225 related articles for article (PubMed ID: 6357436)
21. Amsacrine (m-AMSA): a new antineoplastic agent. Pharmacology, clinical activity and toxicity.
Hornedo J; Van Echo DA
Pharmacotherapy; 1985; 5(2):78-90. PubMed ID: 2582401
[TBL] [Abstract][Full Text] [Related]
22. [Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
Zittoun R; Rio B; Marie JP; Blanc CM
Presse Med; 1985 Jun; 14(26):1417-20. PubMed ID: 3161047
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
Legha SS; Keating MJ; McCredie KB; Bodey GP; Freireich EJ
Blood; 1982 Aug; 60(2):484-90. PubMed ID: 6953987
[TBL] [Abstract][Full Text] [Related]
24. High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia.
Zander AR; Vellekoop L; Dicke KA; Keating MJ; McCredie KB; Legha SS; Spitzer G; Verma D; Bodey GP
Cancer Treat Rep; 1982 Nov; 66(11):1991-2. PubMed ID: 6754077
[No Abstract] [Full Text] [Related]
25. Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia.
Capizzi RL; Powell BL; Cooper MR; Stuart JJ; Muss HB; Richards F; Jackson DV; White DR; Spurr CL; Zekan PJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):105-13. PubMed ID: 3892697
[No Abstract] [Full Text] [Related]
26. A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
Arlin ZA; Ahmed T; Mittelman A; Feldman E; Mehta R; Weinstein P; Rieber E; Sullivan P; Baskind P
J Clin Oncol; 1987 Mar; 5(3):371-5. PubMed ID: 3546613
[TBL] [Abstract][Full Text] [Related]
27. High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.
Cassileth PA; Lyman GH; Bennett JM; Glick JH; Oken MM
Am J Clin Oncol; 1984 Aug; 7(4):361-3. PubMed ID: 6547566
[TBL] [Abstract][Full Text] [Related]
28. Review of amsacrine, an investigational antineoplastic agent.
Grove WR; Fortner CL; Wiernik PH
Clin Pharm; 1982; 1(4):320-6. PubMed ID: 6764391
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of amsacrine (m-AMSA) in advanced ovarian carcinoma.
Dombernowsky P; Siegenthaler P; Somers R; Hansen HH
Eur J Cancer Clin Oncol; 1982 Jan; 18(1):71-4. PubMed ID: 6896306
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of acute leukemia. Current status and perspectives].
Ortega Aramburu JJ
An Esp Pediatr; 1987 Nov; 27(5):319-22. PubMed ID: 3326442
[No Abstract] [Full Text] [Related]
31. Amsacrine (AMSA).
Issell BF
Cancer Treat Rev; 1980 Jun; 7(2):73-83. PubMed ID: 6931632
[No Abstract] [Full Text] [Related]
32. 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Kahn SB; Sklaroff R; Lebedda J; Conroy JF; Bulova S; Brodsky I
Am J Clin Oncol; 1983 Aug; 6(4):493-502. PubMed ID: 6191561
[TBL] [Abstract][Full Text] [Related]
33. High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.
Hines JD; Mazza JJ; Oken MM; Bennett JM; Adelstein DJ; Keller A; O'Connell MJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):117-9. PubMed ID: 3839318
[No Abstract] [Full Text] [Related]
34. Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group.
Winton EF; Hearn EB; Vogler WR; Johnson L; Logan T; Raney M
Cancer Treat Rep; 1983 Nov; 67(11):977-80. PubMed ID: 6580070
[TBL] [Abstract][Full Text] [Related]
35. 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia.
Legha SS; Keating MJ; Zander AR; McCredie KB; Bodey GP; Freireich EJ
Ann Intern Med; 1980 Jul; 93(1):17-21. PubMed ID: 6930826
[TBL] [Abstract][Full Text] [Related]
36. Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
Naparstek E; Shinar E; Polliack A
Isr J Med Sci; 1984 Feb; 20(2):118-22. PubMed ID: 6546740
[TBL] [Abstract][Full Text] [Related]
37. AMSA--a promising new agent in refractory acute leukemia.
Lawrence HJ; Ries CA; Reynolds RD; Lewis JP; Koretz MM; Torti FM
Cancer Treat Rep; 1982 Jul; 66(7):1475-8. PubMed ID: 7046928
[TBL] [Abstract][Full Text] [Related]
38. [Combined therapy with AMSA and etoposide (VP 16-213) in refractory acute myeloid leukemia. A phase I study].
Hiddemann W; Achterrath W; Urbanitz D; Preusser P; Balleisen L; Kirchhof B; Stenzinger W; Büchner T
Onkologie; 1984 Aug; 7(4):214-6. PubMed ID: 6384864
[TBL] [Abstract][Full Text] [Related]
39. m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program.
Weiss RB; Charles LM; Macdonald JS
Cancer Clin Trials; 1980; 3(3):203-9. PubMed ID: 7002337
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of acute childhood leukemia. A new protocol 811 for the high risk group of acute lymphocytic leukemia (Phase III study)].
Mimaya J; Fujimoto T; Hiyoshi Y; Yanai M; Komazawa M; Sekine I; Koizumi S; Nishikawa K; Higashi O; Utsumi J
Rinsho Ketsueki; 1984 Aug; 25(8):1190-6. PubMed ID: 6392601
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]